4D Molecular Therapeutics, Inc. FDMT
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
4D Molecular Therapeutics, Inc. (FDMT) is a healthcare company listed in the US with a market value of about $690M. In the twelve months to September 30, 2026 it had revenue of $96M and net income of -$200M, a net margin of -208.6%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 44% a year, a 5-year average ROIC of -26%.
About 4D Molecular Therapeutics
4D Molecular Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. Revenue went from $7M in 2019 to $85M in 2025, growth of about 51.7% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 79% over three years (dilution for shareholders). It spends 230% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $96M | $85M | $37000 | $21M | $3M | $18M | $14M | $7M |
| Net income | -$200M | -$140M | -$161M | -$101M | -$107M | -$71M | -$57M | -$49M |
| Free cash flow | -$166M | -$110M | -$138M | -$79M | -$98M | -$78M | -$52M | -$40M |
| EPS (diluted) | $-2.70 | $-2.42 | $-2.98 | $-2.58 | $-3.32 | $-2.57 | $-8.82 | $-9.59 |
| Net margin | -208.6% | -164.4% | -434800.0% | -486.6% | -3435.4% | -395.4% | -416.5% | -705.8% |
| ROIC | — | -23.9% | -27.7% | -27.7% | -35.1% | -16.8% | -17.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $28.09, 130% above the current price; targets range from $18.00 to $37.00; the consensus rating is “Strong buy”; expected EPS is $-4.16 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does 4D Molecular Therapeutics pay a dividend?
Not currently.
Is 4D Molecular Therapeutics a good stock to buy?
We do not give buy or sell advice. 4D Molecular Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.